1.Dubberke ER, Olsen MA: Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 2012, 55 Suppl 2:S88–92.
2.Rupnik M, Wilcox MH, Gerding DN: Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009, 7(7):526–536.
3.Cloud, Jeffrey, Kelly, Ciaran: Update on Clostridium difficile associated disease. Current Opinion in Gastroenterology 2007, 23(1):4–9.
4.Setlow P: I will survive: DNA protection in bacterial spores. Trends Microbiol 2007, 15(4):172–180.
5.Calie D, Lee P, al. e: Biocide resistance and transmission of Clostridium difficile spores spiked onto clinical surfaces from an American healthcare facility. Applied and Environmental Microbiology 2019.
6.Depestel DD, Aronoff DM: Epidemiology of Clostridium difficile infection. J Pharm Pract 2013, 26(5):464–475.
7.Barbut F, Petit JC: Epidemiology of Clostridium difficile-associated infections. Clinical Microbiology and Infection 2001, 7(8):405–410.
8.Akerlund T, Svenungsson B, Lagergren A, Burman LG: Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates. J Clin Microbiol 2006, 44(2):353–358.
9.Evans CT, Safdar N: Current Trends in the Epidemiology and Outcomes of Clostridium difficile Infection. Clin Infect Dis 2015, 60 Suppl 2:S66–71.
10.Di Bella S, Ascenzi P, Siarakas S, Petrosillo N, di Masi A: Clostridium difficile Toxins A and B: Insights into Pathogenic Properties and Extraintestinal Effects. Toxins (Basel) 2016, 8(5).
11.Sirard S, Valiquette L, Fortier LC: Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes. J Clin Microbiol 2011, 49(12):4040–4046.
12.Voth DE, Ballard JD: Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005, 18(2):247–263.
13.Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP: The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010, 467(7316):711–713.
14.Aktories K, Papatheodorou P, Schwan C: Binary Clostridium difficile toxin (CDT) - A virulence factor disturbing the cytoskeleton. Anaerobe 2018, 53:21–29.
15.Marvaud JC, Quevedo-Torres S, Eckert C, Janoir C, Barbut F: Virulence of new variant strains of Clostridium difficile producing only toxin A or binary toxin in the hamster model. New Microbes New Infect 2019, 32:100590.
16.Reigadas E, Alcala L, Marin M, Martin A, Iglesias C, Bouza E: Role of binary toxin in the outcome of Clostridium difficile infection in a non–027 ribotype setting. Epidemiol Infect 2016, 144(2):268–273.
17.Merrigan M, Venugopal A, Mallozzi M, Roxas B, Viswanathan VK, Johnson S, Gerding DN, Vedantam G: Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J Bacteriol 2010, 192(19):4904–4911.
18.Collins J, Robinson C, Danhof H, Knetsch CW, van Leeuwen HC, Lawley TD, Auchtung JM, Britton RA: Dietary trehalose enhances virulence of epidemic Clostridium difficile. Nature 2018, 553(7688):291–294.
19.Goorhuis A, Bakker D, Corver J, Debast SB, Harmanus C, Notermans DW, Bergwerff AA, Dekker FW, Kuijper EJ: Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008, 47(9):1162–1170.
20.O’Connor JR, Johnson S, Gerding DN: Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 2009, 136(6):1913–1924.
21.Control CfD: 2015 Anual Report for the Emergin Infections Program for Clostridium difficile Infection. In. Edited by Control CfD; 2015.
22.Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC: Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. The Lancet 2005, 366(9491):1079–1084.
23.Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, Kelly CP: A mouse model of Clostridium difficile-associated disease. Gastroenterology 2008, 135(6):1984–1992.
24.Robinson CD, Auchtung JM, Collins J, Britton RA: Epidemic Clostridium difficile strains demonstrate increased competitive fitness compared to nonepidemic isolates. Infect Immun 2014, 82(7):2815–2825.
25.Vohra P, Poxton IR: Comparison of toxin and spore production in clinically relevant strains of Clostridium difficile. Microbiology 2011, 157(Pt 5):1343–1353.
26.Hunt JJ, Ballard JD: Variations in virulence and molecular biology among emerging strains of Clostridium difficile. Microbiol Mol Biol Rev 2013, 77(4):567–581.
27.Burns DA, Heap JT, Minton NP: The diverse sporulation characteristics of Clostridium difficile clinical isolates are not associated with type. Anaerobe 2010, 16(6):618–622.
28.Burns DA, Heeg D, Cartman ST, Minton NP: Reconsidering the sporulation characteristics of hypervirulent Clostridium difficile BI/NAP1/027. PLoS One 2011, 6(9):e24894.
29.Hutton ML, Mackin KE, Chakravorty A, Lyras D: Small animal models for the study of Clostridium difficile disease pathogenesis. FEMS Microbiol Lett 2014, 352(2):140–149.
30.Buckley AM, Spencer J, Candlish D, Irvine JJ, Douce GR: Infection of hamsters with the UK Clostridium difficile ribotype 027 outbreak strain R20291. J Med Microbiol 2011, 60(Pt 8):1174–1180.
31.Buckley AM, Spencer J, Maclellan LM, Candlish D, Irvine JJ, Douce GR: Susceptibility of hamsters to Clostridium difficile isolates of differing toxinotype. PLoS One 2013, 8(5):e64121.
32.Best EL, Freeman J, Wilcox MH: Models for the study of Clostridium difficile infection. Gut Microbes 2012, 3(2):145–167.
33.Basson M, al. e: Effect of tyrosine kinase inhibition on basal and epidermal growth factor‐stimulated human Caco‐2 enterocyte sheet migration and proliferation. Journal of Cellular Physiology 1994, 160(3):491–501.
34.Peterson M, Mooseker M: Characterization of the enterocyte-like brush border cytoskeleton of the C2BBe clones of the human intestinal cell line, Caco–2. J Cell Sci 1992, 102:581–600.
35.Akerlund T, Persson I, Unemo M, Noren T, Svenungsson B, Wullt M, Burman LG: Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1. J Clin Microbiol 2008, 46(4):1530–1533.
36.Lanis JM, Heinlen LD, James JA, Ballard JD: Clostridium difficile 027/BI/NAP1 encodes a hypertoxic and antigenically variable form of TcdB. PLoS Pathog 2013, 9(8):e1003523.
37.Morgan OW, Rodrigues B, Elston T, Verlander NQ, Brown DF, Brazier J, Reacher M: Clinical severity of Clostridium difficile PCR ribotype 027: a case-case study. PLoS One 2008, 3(3):e1812.
38.Curry SR, Marsh JW, Muto CA, O’Leary MM, Pasculle AW, Harrison LH: tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J Clin Microbiol 2007, 45(1):215–221.
39.Dupuy B, Govind R, Antunes A, Matamouros S: Clostridium difficile toxin synthesis is negatively regulated by TcdC. J Med Microbiol 2008, 57(Pt 6):685–689.
40.Calderon-Romero P, Castro-Cordova P, Reyes-Ramirez R, Milano-Cespedes M, Guerrero-Araya E, Pizarro-Guajardo M, Olguin-Araneda V, Gil F, Paredes-Sabja D: Clostridium difficile exosporium cysteine-rich proteins are essential for the morphogenesis of the exosporium layer, spore resistance, and affect C. difficile pathogenesis. PLoS Pathog 2018, 14(8):e1007199.
41.Mora-Uribe P, Miranda-Cardenas C, Castro-Cordova P, Gil F, Calderon I, Fuentes JA, Rodas PI, Banawas S, Sarker MR, Paredes-Sabja D: Characterization of the Adherence of Clostridium difficile Spores: The Integrity of the Outermost Layer Affects Adherence Properties of Spores of the Epidemic Strain R20291 to Components of the Intestinal Mucosa. Front Cell Infect Microbiol 2016, 6:99.
42.Paredes-Sabja D, Shen A, Sorg JA: Clostridium difficile spore biology: sporulation, germination, and spore structural proteins. Trends Microbiol 2014, 22(7):406–416.
43.Kochan TJ, Somers MJ, Kaiser AM, Shoshiev MS, Hagan AK, Hastie JL, Giordano NP, Smith AD, Schubert AM, Carlson PE, Jr. et al: Intestinal calcium and bile salts facilitate germination of Clostridium difficile spores. PLoS Pathog 2017, 13(7):e1006443.
44.Theriot CM, Young VB: Interactions between the gastrointestinal microbiome and Clostridium difficile. Annu Rev Microbiol 2015, 69:445–461.
45.Cowardin CA, Buonomo EL, Saleh MM, Wilson MG, Burgess SL, Kuehne SA, Schwan C, Eichhoff AM, Koch-Nolte F, Lyras D et al: The binary toxin CDT enhances Clostridium difficile virulence by suppressing protective colonic eosinophilia. Nat Microbiol 2016, 1(8):16108.
46.Bidet P, Barbut F, al. e: Development of a new PCR-ribotyping method for Clostridium di¤cile based on ribosomal RNA gene sequencing. Microbiology Letters 1999, 175:261–266.
47.Fawley WN, Knetsch CW, MacCannell DR, Harmanus C, Du T, Mulvey MR, Paulick A, Anderson L, Kuijper EJ, Wilcox MH: Development and validation of an internationally-standardized, high-resolution capillary gel-based electrophoresis PCR-ribotyping protocol for Clostridium difficile. PLoS One 2015, 10(2):e0118150.
48.Wilson K, Kennedy M, Fekety F: Use of sodium taurocholate to enhance spore recovery on a medium selective for Clostridium difficile. Journal of Clinical Microbiology 1982, 15(3):443–446.
49.Paredes-Sabja D, Bond C, Carman RJ, Setlow P, Sarker MR: Germination of spores of Clostridium difficile strains, including isolates from a hospital outbreak of Clostridium difficile-associated disease (CDAD). Microbiology 2008, 154(Pt 8):2241–2250.